Recent advances in the treatment of malignant astrocytoma.
Malignant gliomas, including the most common subtype, glioblastoma multiforme (GBM), are among the most devastating of neoplasms. Their aggressive infiltration in the CNS typically produces progressive and profound disability--ultimately leading to death in nearly all cases. Improvement in outcome has been elusive despite decades of intensive clinical and laboratory research. Surgery and radiotherapy, the traditional cornerstones of therapy, provide palliative benefit, while the value of chemotherapy has been marginal and controversial. Limited delivery and tumor heterogeneity are two fundamental factors that have critically hindered therapeutic progress. A novel chemoradiotherapy approach, consisting of temozolomide administered concurrently during radiotherapy followed by adjuvant systemic temozolomide, has recently demonstrated a meaningful, albeit modest, improvement in overall survival for newly diagnosed GBM patients. As cell-signaling alterations linked to the development and progression of gliomas are being increasingly elucidated, targeted therapies have rapidly entered preclinical and clinical evaluation. Responses to therapies that function via DNA damage have been associated with specific mediators of resistance that may also be subject to targeted therapies. Other approaches include novel locoregional delivery techniques to overcome barriers of delivery. The simultaneous development of multiple advanced therapies based on specific tumor biology may finally offer glioma patients improved survival.
Reardon
David A
DA
Preston Robert Tisch Brain Tumor Center at Duke University, Duke University Medical Center, Durham, NC 27710, USA. reard003@mc.duke.edu
Rich
Jeremy N
JN
Friedman
Henry S
HS
Bigner
Darell D
DD
D000970:Antineoplastic Agents / Q000627:therapeutic use; D001254:Astrocytoma / Q000235:genetics / Q000378:metabolism / Q000628:therapy*; D016543:Central Nervous System Neoplasms / Q000235:genetics / Q000378:metabolism / Q000628:therapy*; D003131:Combined Modality Therapy; D019175:DNA Methylation; D003606:Dacarbazine / Q000031:analogs & derivatives / Q000627:therapeutic use; D006801:Humans; D000077204:Temozolomide
D000970:Antineoplastic Agents; D003606:Dacarbazine; D000077204:Temozolomide